Skip to Main Content
TRC_PLH
Menu
    • Products
      • CriticalPoint
      • Hospital Pharmacist's Letter
      • Hospital Pharmacy Technician's Letter
      • Learning Management Portal
      • NatMed Advisor
      • NatMed Pro
      • NetCE All Access
      • NetCE All Access: Behaviorial Health
      • Pharmacist's Letter
      • Pharmacist's Letter Canada
      • Pharmacy Technician's Letter
      • Pharmacy Technician's Letter Canada
      • Prescriber Insights
      • RxAdvanced
      • RxSelect

    Subscribe Login
  • Home
  • Letter
    • Current Issue
    • Past Issues
    • Suggest a Topic
  • Browse
    • Subject
    • Featured Charts & Graphics
    • Gender-Related Care
    • Diabetes Resources
    • Immunization Resources
    • Natural Medicines Resources
    • All Charts & Graphics
  • Podcasts
  • Charts & Graphics
    • Featured Charts & Graphics
    • Diabetes Drugs
    • Do Not Crush List
    • IV Fluid Safety
    • New Drugs
    • Opioid Dosing
    • Vancomycin Dosing
    • All Charts & Graphics >
  • CE/CME & Training
    • CE Organizer
    • Available Courses
    • My Completions
    • Live Webinars
  • Help
    • User Support
    • Contact Us

Upgrade Your Browser

We no longer support this version of your browser. We recommend that you upgrade to the latest version of Internet Explorer, Firefox, Chrome or Safari to improve your security and experience using this website.

Return to the course you were viewing

NatMed Pro, the largest natural medicines database, just got a major upgrade! With faster performance, a redesigned interface, and improved navigation, it's easier than ever to find the evidence-based answer you need. Explore Now
Become a smarter pharmacist in minutes! More CE, more resources, more value. Choose your Hospital Pharmacist's Letter membership and elevate your pharmacy practice today. Subscribe Now
  1. Home
  2. Browse
  3. Diabetes & Endocrinology
  4. Diabetes
  5. Treatment

Treatment

  • Diabetes (396)
    • Blood Glucose Meters (4)
    • Complications (136)
    • Diabetes in Pregnancy (6)
    • Diabetes Meds (71)
    • Drug-Induced Hypo/Hyperglycemia (114)
    • Monitoring (80)
    • Natural Medicines/Supplements (7)
    • Prevention (26)
    • Treatment (238)
      • Alpha-Glucosidase Inhibitors (20)
      • Amylin Agonist (12)
      • Bromocriptine (7)
      • Combination Products (10)
      • Gliptins (60)
      • Glitazones (86)
      • GLP-1 (33)
      • Incretin Enhancers/Mimetics (51)
      • Insulin (127)
      • Meglitinides (33)
      • Metformin (100)
      • SGLT2 Inhibitors (78)
      • Sulfonylureas (83)
      • Treatment of Pediatric Metabolic Syndrome (3)
  • Endocrinology (10)
  • Hyperglycemia (38)
  • Hypoglycemia (20)
  • Other (16)
  • Prediabetes (1)
  • Resources (173)
  • Thyroid Disorders (24)
211 - 225 of 238 Results
Sort Results:
  • Title: Ascending (A-Z)
  • Date: Newest First
  • Date: Oldest First
Commentary: Have Meds Will Travel August 2012
PL Voices: Management of Type 2 Diabetes in Kids and Teens July 2012
Guideline: Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada July 2012
PL Voices: Choosing Diabetes Meds to Add to Metformin June 2012
Guideline: Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach (2012) June 2012
Other: Stepwise Approach to Selecting Treatments for Type 2 Diabetes (ADA) June 2012
PL Voices: New Once WEEKLY Exenatide (Bydureon) March 2012
Commentary: Using Exenatide (Byetta) with Insulin Glargine (Lantus) December 2011
Commentary: Diabetes Meds and Cardiovascular Risk November 2011
Commentary: Actos (Pioglitazone) and Increased Risk of Bladder Cancer July 2011
Guideline: Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy (2009) June 2011
Commentary: New Drug: Tradjenta (Linagliptin) June 2011
Commentary: Metformin vs Pioglitazone for Polycystic Ovary Syndrome May 2011
Commentary: Cycloset: A New Bromocriptine Formulation for Diabetes February 2011
Commentary: Actos (Pioglitazone) and Risk of Bladder Cancer October 2010
  • « Prev
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • Next »
  • About Us
  • Our Mission
  • Our Team
  • Careers
  • Newsroom
  • Products
  • Pharmacist Solutions
  • Prescriber Solutions
  • Hospital Solutions
  • Retail Solutions
  • Group Practice Solutions
  • Support & Policies
  • Contact Us
  • Access Agreement
  • Privacy Policy

The contents of this website are not intended to be a substitute for professional medical advice, diagnosis, or treatment. See additional information.



© Therapeutic Research Center. All Rights Reserved